Investment
Features
FeesSafety
Academy
More
Pluang+

Four Corners Property Trust stays a Buy with strong diversification and 6.36% dividend yield despite macro challenges.

Market News
18 Sep 2026
Seeking Alpha
View Source
Bullish
Four Corners Property Trust stays a Buy with strong diversification and 6.36% dividend yield despite macro challenges.

Four Corners Property Trust (FCPT) maintains a Buy rating due to its ongoing portfolio diversification and a solid margin of safety compared to its intrinsic value. The company has acquired $382 million in assets year-to-date at a 6.6% blended cap rate, expanding beyond its concentration in Darden Restaurants. Despite facing short-term macroeconomic headwinds and higher borrowing costs, FCPT offers an attractive monthly dividend yield of approximately 6.36% supported by a strong balance sheet. Limited new retail real estate supply may drive future rent growth, enhancing FCPT’s long-term recovery and growth potential.

Four Corners Property Trust provides context for real estate investors. For readers following this sector, here is Pluang's market snapshot as of Sep 18, 2026 19:12 WIB: Among 25 priced US real estate stocks, 15 rose and 8 fell. Notable movers include JLL at USD 337.68 (+0.25%), VICI at USD 24.05 (-0.24%) with 100% buy order activity, and IIPR at USD 56.51 (+0.21%) also with 100% buy order activity and a typical hold time of 85 days.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
32 minutes ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App